- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00841269
Oral Uridine for Treatment of Bipolar Depression in Adolescents
Oral Administration of Uridine for Treatment of Bipolar Depression in Adolescents: A Magnetic Resonance Spectroscopy Study
Study Overview
Detailed Description
This is an open-label study of the investigational drug uridine in the treatment of adolescents with depression with bipolar disorder. Uridine has shown positive results in a Phase II study of bipolar disorder in adults (http://clinicaltrials.gov/ct2/show/NCT00322764). This study will enroll 30 depressed adolescent participants who meet DSM-IV-TR criteria for bipolar disorder type I, type II or bipolar disorder not otherwise specified. Participants who are currently taking psychotropic medication(s) will continue on their current regimen, with uridine added as adjunctive therapy. Participants who are untreated will be informed of the alternatives to study participation. This will include informing the parent(s) or guardian(s) that Lithium, Risperdal and Abilify are FDA-approved treatments for adolescent bipolar disorder that would be available to their child in community care.
The study has three objectives: 1) To use Magnetic Resonance Spectroscopy (MRS) brain imaging to measure levels of beta-nucleoside triphosphate (b-NTP) in the anterior cingulate cortex of 30 adolescents with bipolar disorder, before-and-after 6 weeks of treatment with the investigational drug uridine; 2) To measure the antidepressant response to uridine in the 30 participants with the Children's Depression Rating Scale (CDRS); and 3) To acquire structural Magnetic Resonance Imaging (MRI) data in the 30 participants with bipolar disorder and the 30 healthy controls, to establish regionally-specific structure/neurochemical relationships.
Adolescent participants with bipolar disorder will be treated with uridine 500mg twice daily for six weeks. The primary clinical outcome measure is the Children's Depression Rating Scale (CDRS), with response defined as a 30% reduction in CDRS score. In addition to this standardized clinical assessment, participants will undergo magnetic resonance imaging and magnetic resonance spectroscopy (MRI/MRS) brain scans at baseline, and after six weeks of treatment with uridine. This novel approach is designed to explore objectively measurable biomarkers of illness and treatment response in pediatric bipolar disorder. The investigators hypothesize that participants whose depression responds to uridine will demonstrate an increased concentration of beta-nucleoside triphosphate (b-NTP) in the anterior cingulate cortex. This would support the hypothesis that depressive states are associated with abnormalities in brain energy metabolism.
As a neuroimaging comparison group for the participants with bipolar disorder, 30 healthy adolescent controls with no history of psychiatric illness will be recruited for MRI/MRS scanning only. The investigators hypothesize that controls will have higher levels of b-NTP in the anterior cingulate cortex than participants with depression associated with bipolar disorder, further supporting a connection between brain bioenergetics and depression.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University Of Utah School Of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Selection of Participants with Bipolar Disorder:
Inclusion Criteria:
- Participants must meet DSM-IV-TR (American Psychiatric Association, 2000) criteria for Bipolar Disorder Type I, Type II, or Not Otherwise Specified (NOS) with current mood state depressed for > 2 weeks
- Participants must be between the age of 13 and 18 years
- Participants who enter the study on psychotropic medications must be on a regimen that has been stable for > 2 weeks at the time of study entry
- Participants must be able to give informed consent or assent, and parent(s)/guardian(s) must be able to give informed permission for study participation
Exclusion Criteria:
- Adolescents with an unstable co-morbid medical, neurological, or psychiatric disorder
- Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice contraception during the study
- Participants with high risk of suicidal behaviors, homicidal behaviors, or self-harm
- Participants who in the opinion of the investigator are unlikely to be able to comply with the study protocol
- Participants who meet DSM-IV-TR criteria for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence
- Participants for whom the MRI/MRS scans are contraindicated, such as children with ferromagnetic implants or claustrophobia
- Participants whose mood state is manic
- Documented or suspected history of mental retardation (IQ<70)
- Positive urine drug screen for cocaine or amphetamines
- Known hypersensitivity to uridine
Selection of Healthy Volunteers:
Inclusion Criteria:
- Participants must be between the ages of 13 and 18 years
- Participants must not meet DSM-IV-TR diagnostic criteria for a mental disorder or substance abuse
- Participants must be able to give informed consent or assent and parents/guardians must be able to give informed permission for participation
Exclusion Criteria:
- Clinically significant medical, neurological, psychiatric or substance abuse disorder
- Pregnant subjects, due to the unknown effects of MRI/MRS scans on a fetus. In addition, women of childbearing potential who are unable or unwilling to practice contraception during the study will be excluded. Female participants who are of child-bearing potential must have a negative urine pregnancy test before each MRI/MRS scan.
- Participants with a contraindication to MRI/MRS scanning, such as a metallic implant
- Patients unable to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Uridine
Uridine 500 mg by mouth twice daily for 6 weeks
|
Uridine 500 mg by mouth twice per day for 6 weeks
|
No Intervention: Healthy Comparison
Healthy comparison participants were seen for baseline and week 6 MRI scans.
No treatment was administered to participants enrolled as healthy comparisons.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Scores in Children's Depression Rating Scale (CDRS-R), Assessed Before and After 6 Week Uridine Treatment
Time Frame: 6 weeks
|
The CDRS-R is a 17-item scale, with items rated for severity on a 5 point scale for 3 items and on a 7 point scale for 14 items (possible total score from 17 to 113).
Ratings are completed by a clinician via interviews with the child or parent.
Scores ≥40 are indicative of depression, whereas scores ≤28 is often used to define remission.
|
6 weeks
|
The Primary Neuroimaging Outcome Will be Changes in Beta-NTP to TP (Total Phosphorus) Ratio in the Anterior Cingulate.
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A Secondary Outcome Measure Includes a Change in Young Mania Rating Scale (YMRS) Score
Time Frame: 6 weeks
|
The Young Mania Rating Scale (YMRS) is an 11-item rating scale that evaluates manic symptoms.
Total scores range from 0-60, with higher scores indicating more manic symptoms endorsed by research participants.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Douglas G Kondo, M.D., University of Utah
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 28455
- 5R01MH058681-06 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
Clinical Trials on Uridine
-
Repligen CorporationCompletedBipolar DepressionUnited States
-
VA Office of Research and DevelopmentActive, not recruitingSuicidal IdeationUnited States
-
National Center for Research Resources (NCRR)University of California, San DiegoCompleted
-
University of UtahThe Depressive and Bipolar Disorder Alternative Treatment FoundationCompletedBipolar Disorder | Bipolar Depression | Manic DepressionUnited States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Wellstat TherapeuticsApproved for marketing
-
Wellstat TherapeuticsCompletedHereditary Orotic AciduriaUnited States
-
National Center for Complementary and Integrative...CompletedHIV Infections | Insulin Resistance | HyperlactatemiaUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Mclean HospitalNational Institute of Mental Health (NIMH)CompletedHealthy Male SubjectsUnited States